Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

1146 - Prognostic value of disseminated tumor cells (DTC) identification in bone marrow from patients with advanced gastric or esophagogastric junction (EGJ) adenocarcinoma (interim results)


19 Dec 2015


Poster presentation 1


Ekaterina Obarevich


Annals of Oncology (2015) 26 (suppl_9): 8-15. 10.1093/annonc/mdv518


E.S. Obarevich1, N.S. Besova2, N.N. Tupitsyn3, M.M. Davydov4, V.A. Gorbunova2, T.A. Titova2

Author affiliations

  • 1 Chemotherapy, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 2 Chemotherapy, N. N. Blokhin Russian Cancer Research Center, Moscow/RU
  • 3 Haematopoiesis Immunology Lab., N. N. Blokhin Russian Cancer Research Center, Moscow/RU
  • 4 Thoraco-abdominal, N. N. Blokhin Russian Cancer Research Center, Moscow/RU


Abstract 1146


To identify DTC in bone marrow (BM) as a therapeutically significant target to predict survival of patients with stage IV gastric cancer.


A total of 27 patients with advanced gastric cancer were enrolled, median age 52 years. All patients received thriplet chemotherapy. Baseline BM-DCT were identified by flow cytometry. BM-DTC positivity was defined as at least 1 tumor cell per 10 million myelokaryocytes.


BM-DTC were found in 18 of 27 patients. Median survival was 6.5 months in BM-DTC positive vs. 9.2 months in BM-DTC negative patients (p = 0.019). The table below summarizes the clinicomorphological findings. Table. Relationship between DTC-positivity and clinicomorphological parameters.

Parameter BM-DTC positive patients n, % BM-DTC negative patients n, % p-Value
Tumor site
Esophagogastric junction 9/18 (50) 1/9 (11.1) 0.049
Body of stomach 6/18 (33.3) 4/9 (44.4) 0.573
Anthrum 3/18 (16.7) 2/9 (22.2) 0.726
Total stomach 0/18 (0) 2/9 (22.2) 0.038
Adenocarcinoma histology
Moderately differentiated 4/18 (22.2) 2/9 (22.2) 1
Poorly differentiated 10/18 (55.6) 1/9 (11.1) 0.027
Signet-ring cell 4/18 (22.2) 6/9 (66.7) 0.024
Metastasis sites
Liver 6/18 (33.3) 3/9 (33.3) 1
Peripheral lymph nodes 4/18 (22.2) 3/9 (33.3) 0.535
Retroperitoneal lymph nodes 8/18 (44.4) 2/9 (22.2) 0.260
Ovaries 1/18 (5.6) 1/9 (11.1) 0.603
Peritoneal carcinomatosis 9/18 (50) 8/9 (88.9) 0.049


The presence of DTC in BM of patients with advanced gastric cancer is a poor prognostic factor associated with a high risk of early progression. BM-DTC were identified significantly more frequently in cases with EGJ and total gastric cancer, and in patients free from peritoneal carcinomatosis; there was also a correlation with tumor histology. The study is in ongoing

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings